Abselion establishes a US subsidiary in Massachusetts
Lucy Batizovsky | March 10, 2026 | News story | Research and Development | Abselion, The Engine, US
Abselion has established a US subsidiary at The Engine in Cambridge, Massachusetts in the US.
The company aims to strengthen its presence in the US life sciences ecosystem through the addition of a formal base to support more direct engagement with academic, biotech and pharmaceutical research teams.
Dr Ruizhi Wang, CEO and Founder, Abselion, said: “Our vision is to make high-quality quantification more accessible through closer international collaboration. Establishing a US subsidiary marks an important milestone in Abselion’s growth, strengthening our ability to operate across key life science markets globally while continuing to build on our strong scientific foundation.”
This subsidiary will align Abselion’s organisational structure with the geographic distribution of its customer base, allowing the company to plan and coordinate its North American activities more effectively.
“The US represents a significant focus for advanced biologics research and development. A formal presence there demonstrates our commitment to supporting long-term adoption of our protein quantification systems and will allow our growing international team to work more closely with customers and partners as they explore and build workflows around our Amperia platform,” Wang added.
The new location is based at The Engine, built by the Massachusetts Institute of Technology (MIT), a Tough Tech incubator and accelerator providing a strategic US hub for life sciences, biotech and other transformational technologies.
Founded in Cambridge, UK, Abselion is supported by competitive innovation programmes such as Innovate UK and the National Research Council (NRC), enabling data-driven decisions across life sciences, biotech and therapeutic development.
Related Content
ESTEVE CDMO commences $15.5m expansion of US facility
ESTEVE CDMO, a global Contract Development and Manufacturing Organization (CDMO) specialising in small molecule active pharmaceutical …
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase …
